Genomic Determinants of Outcome in Cardiogenic Shock

Recruiting now

Conditions studied: Cardiogenic Shock

In brief

The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.

Key facts

Study ID

NCT05728359

Run by

Barts & The London NHS Trust

People needed

300

Starts

2022-08-08

Expected to finish

2026-12-31

Last updated by the study team

2025-11-18

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All of the following are required for inclusion following screening:
• Willing to provide informed consent or appropriate consent from a nominated consultee or personal consultee
• Presentation within 24 hours of onset of ACS symptoms.
• CS can only be secondary to ACS (Type 1 MI STEMI or N-STEMI) or myocarditis
• Planned or completed revascularisation of culprit coronary artery
• CS will be defined by:
• Systolic blood pressure <90 mmHg for at least 30 minutes
• A requirement for a continuous infusion of vasopressor or inotropic therapy to maintain systolic blood pressure > 90 mmHg.
• Clinical signs of pulmonary congestion, plus signs of impaired organ perfusion with at least one of the following manifestations:
• altered mental status.
• cold and clammy skin and limbs.
• oliguria with a urine output of less than 30 ml per hour.
• elevated arterial lactate level of >2.0 mmol per litre.

You may not qualify if…

• Any of the inclusion criteria not met and:
• Unwilling to provide informed consent.
• Echocardiographic evidence (recorded within 90 mins of end of PCI procedure) of mechanical cause for CS: eg ventricular septal defect, LV-free wall rupture, ischaemic mitral regurgitation.
• Age <18 and ≥80 years.
• Shock from another cause (sepsis, haemorrhagic/hypovolaemic shock, anaphylaxis, etc).
• Significant systemic illness
• Known dementia of any severity
• Comorbidity with life expectancy <12 months.
• Out-of-hospital cardiac arrest (OHCA) and any of the following:
• No return of spontaneous circulation (ongoing resuscitation effort)
• pH <7
• Without bystander CPR within 10 minutes of collapse
• Arterial lactate level of <2.0 mmol per litre.

Where it is running

• Barts Health NHS trust — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.